$55M Bet On Archer Aviation? Check Out These 3 Penny Stocks Insiders Are Aggressively Buying

The Dow Jones index closed lower by around 0.1% on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company’s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga’s insider transactions platform.

Allied Gaming & Entertainment

  • The Trade: Allied Gaming & Entertainment Inc. AGAE 10% owner Knighted Pastures LLC bought a total of 360,000 shares at an average price of $1.27. To acquire these shares, it cost around $456,750.
  • What's Happening: Allied Gaming & Entertainment, on June 15, entered into a termination agreement with Elite Fun Entertainment Limited and its affiliates.
  • What Allied Gaming & Entertainment Does: Allied Gaming & Entertainment Inc is an experiential entertainment company focused on providing a growing world of gamers with various experiences through renowned assets, products, and services.

Archer Aviation

  • The Trade: Archer Aviation Inc. ACHR 10% owner SFS UK 1 LTD. acquired a total of 17,401,153 shares at an average price of $3.16. To acquire these shares, it cost around $55 million.
  • What's Happening: On July 2, Archer Aviation announced it received an additional $55 million investment from Stellantis following its recent flight test milestone.
  • What Archer Aviation Does: Archer Aviation Inc advances the benefits of sustainable air mobility. The company is engaged in designing and developing a fully electric vertical takeoff and landing eVTOL aircraft for use in UAM networks.

Tempest Therapeutics

  • The Trade: Tempest Therapeutics, Inc. TPST Chief Medical Officer Samuel Whiting acquired a total of 4,672 shares at an average price of $2.13. The insider spent around $9,951 to buy those shares.
  • What's Happening: On June 20, The company announced data from the ongoing global randomized Phase 1b/2 clinical study for amezalpat2.
  • What Tempest Therapeutics Does: Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity.

Read More: Top 3 Health Care Stocks That May Crash This Quarter

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: Long IdeasNewsPenny StocksInsider TradesPre-Market OutlookMarketsTrading IdeasInsider Buying
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!